Premium
LOPP chemotherapy as a first‐line treatment for dogs with T‐cell lymphoma
Author(s) -
Brown P. M.,
Tzannes S.,
Nguyen S.,
White J.,
Langova V.
Publication year - 2018
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12318
Subject(s) - lomustine , procarbazine , vincristine , medicine , chop , chemotherapy , prednisolone , lymphoma , gastroenterology , t cell lymphoma , canine lymphoma , oncology , toxicity , surgery , cyclophosphamide
Background The aim of this study was to describe the use of a lomustine ( CCNU ), vincristine, procarbazine and prednisolone ( LOPP ) protocol used for treatment of chemotherapy naive T‐cell lymphoma patients and to describe the response rate, toxicity and disease‐free interval compared historically to CHOP chemotherapy. Materials and Methods Retrospective case study of 31 dogs with naïve T‐cell lymphoma treated with a lomustine ( CCNU ), vincristine, procarbazine and prednisolone ( LOPP ) protocol. Results Thirty‐one dogs with T cell lymphoma were treated. The overall response rate was 97%. Of the 30 dogs that had a response to LOPP chemotherapy, the median disease free interval was 176 days (range 0–1745 days). The median overall survival time for this study group was 323 days (range 51–1758 days). All deaths in this study were attributable to lymphoma. Conclusion LOPP chemotherapy for T cell lymphoma is well tolerated with a low toxicity profile and an excellent overall response rate. This protocol showed minimal toxicity and comparable disease free interval and survival times for canine high grade T cell lymphoma treated with CHOP .